Peroxidase-mediated dealkylation of tamoxifen, detected by electrospray ionization-mass spectrometry, and activation to form DNA adducts

Free Radical Biology and Medicine

Volumn 52, Issue 2, 2012, Pages 340-347

  Gaikwad, Nilesh W ^a   Bodell, William J ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Contrast Therapeutics ^*  (United States)

Author keywords

DNA adducts; ESI MS MS; Free radicals; HRP; Metabolite E; Peroxidase; Quinone methide; Tamoxifen; UPLC

Indexed keywords

ASCORBIC ACID; DNA; HORSERADISH PEROXIDASE; PEROXIDASE; TAMOXIFEN;

ARTICLE; CHEMICAL REACTION; CHROMATOGRAPHY; CONTROLLED STUDY; DEALKYLATION; DNA ADDUCT; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; METABOLITE; NONHUMAN; OXIDATION; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, HORMONAL; BIOTRANSFORMATION; DEALKYLATION; DNA; DNA ADDUCTS; HORSERADISH PEROXIDASE; HYDROGEN PEROXIDE; QUINONES; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TAMOXIFEN; TANDEM MASS SPECTROMETRY;

ARMORACIA RUSTICANA;

EID: 84855431362     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2011.10.433     Document Type: Article

References (66)

1. V.C. Jordan, and A.M.H. Brodie Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer Steroids 72 2007 7 25 (Pubitemid 46037765)
2. R. Ponzone, N. Biglia, M.E. Jacomuzzi, L. Mariani, A. Dominguez, and P. Sismondi Antihormones in prevention and treatment of breast cancer Ann. N. Y. Acad. Sci. 1089 2006 143 158 (Pubitemid 47092092)
3. J. Cuzick Chemoprevention of breast cancer Womens Health 2 2006 853 861 (Pubitemid 44816836)
4. 32P-postlabeling Cancer Res. 59 1999 4829 4833 (Pubitemid 29472884)
5. A. Umemoto, K. Komaki, Y. Monden, M. Suwa, Y. Kanno, M. Kitagawa, M. Suzuki, C.X. Lin, Y. Ueyama, M.A. Momen, A. Ravindernath, and S. Shibutani Identification and quantification of tamoxifen-DNA adducts in the liver of rats and mice Chem. Res. Toxicol. 14 2001 1006 1013 (Pubitemid 32800156)
6. S. Shibutani, N. Suzuki, Y.R. Laxmi, L.J. Schild, R.L. Divi, A.P. Grollman, and M.C. Poirier Identification of tamoxifen-DNA adducts in monkeys treated with tamoxifen Cancer Res. 63 2003 4402 4406 (Pubitemid 36951010)
7. L.L. Smith, and I.N. White Antiestrogen therapy: uncertainties and risk assessment Oncology 12 1998 14 22
8. U. Magriples, F. Naftolin, P.E. Schwartz, and M.L. Carcangice High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients J. Clin. Oncol. 11 1993 485 490 (Pubitemid 23071046)
9. B. Fisher, J.P. Constantino, C.K. Remond, E.R. Fisher, D.L. Wickerham, and W.M. Cronin Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 J. Natl. Cancer Inst. 86 1994 527 537 (Pubitemid 24111008)
10. L.S. Cook, N.S. Weiss, S.M. Schwartz, E. White, B. Mc Knight, and D.E. Moore Population-based study of tamoxifen therapy and subsequent ovarian, endometrial and breast cancers J. Natl. Cancer Inst. 87 1995 1359 1364
11. R.E. Curtis, J.D. Boise Jr., D.A. Shriner, B.F. Hanky, and J.F. Fraumen Jr. Second cancers after adjuvant tamoxifen therapy for breast cancer J. Natl. Cancer Inst. 88 1996 832 834 (Pubitemid 26187392)
12. S. Borgquist, L. Anagnostaki, K. Jirstroem, G. Landberg, and J. Manjer Breast tumors following combined hormone replacement therapy express favorable prognostic factors Int. J. Cancer 120 2007 2202 2207 (Pubitemid 46555859)
13. A.M. Chiarelli, V.A. Kirsh, N.S. Klar, R. Shumak, R. Jong, E. Fishell, M.J. Yaffe, and N.F. Boyd Influence of patterns of hormone replacement therapy use and mammographic density on breast cancer detection Cancer Epidemiol. Biomarkers 15 2006 1856 1862 (Pubitemid 44664260)
14. Y.-W. Huang, J.R. Phillips, and L.D. Hunter Human exposure to medicinal, dietary, and environmental estrogens Toxicol. Environ. Chem. 89 2007 141 160 (Pubitemid 44949988)
15. G.C. Hard, M.J. Iatropoulos, K. Jordan, L. Radi, O.P. Kaltenberg, A.R. Imondi, and G.M. Williams Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats Cancer Res. 53 1993 4534 4541 (Pubitemid 23304376)
16. M.R. Osborne, A. Hewer, I.R. Hardcastle, P.L. Carmichael, and D.H. Phillips Identification of the major tamoxifen-deoxyguanosine adduct formed in the liver DNA of rats treated with tamoxifen Cancer Res. 56 1996 66 71 (Pubitemid 26010385)
17. R. Davies, V.I. Oreffo, E.A. Martin, M.F. Festing, I.N. White, L.L. Smith, and J.A. Styles Tamoxifen causes gene mutations in the livers of lambda/lacI transgenic rats Cancer Res. 57 1997 1288 1293 (Pubitemid 27152553)
18. R. Davies, T.W. Gant, L.L. Smith, and J.A. Styles Tamoxifen induces G:C → T:A mutations in the cII gene in the liver of lambda/lacI transgenic rats but not at 5′-CpG-3′ dinucleotide sequences as found in the lacI transgene Carcinogenesis 20 1999 1351 1356 (Pubitemid 29341460)
19. G. Gamboa da Costa, L.P. McDaniel-Hamilton, R.H. Heflich, M.M. Marques, and F.A. Beland DNA adduct formation and mutant induction in Sprague-Dawley rats treated with tamoxifen and its derivatives Carcinogenesis 22 2001 1307 1315 (Pubitemid 32737349)
20. G. Gamboa da Costa, M.G. Manjanatha, M.M. Marques, and F.A. Beland Induction of lacI mutations in Big Blue rats treated with tamoxifen and alpha-hydroxytamoxifen Cancer Lett. 176 2002 37 45 (Pubitemid 34085068)
21. G.M. Williams, M.J. Iatropoulos, M.V. Djordjevic, and O.P. Kaltenberg The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat Carcinogenesis 14 1993 315 317 (Pubitemid 23143415)
22. L.J. Schild, R.L. Divi, F.A. Beland, M.I. Churchwell, D.R. Doerge, G. Gamboa da Costa, M.M. Marques, and M.C. Poirier Formation of tamoxifen-DNA adducts in multiple organs of adult female cynomolgus monkeys dosed with tamoxifen for 30 days Cancer Res. 63 2003 5999 6003 (Pubitemid 37187502)
23. M. Sharma, D.E. Shubert, M. Sharma, K.J. Rodabaugh, B.P. McGarrigle, C.M. Vezina, D.P. Bofinger, and J.R. Olson Antioxidant inhibits tamoxifen-DNA adducts in endometrial explant culture Biochem. Biophys. Res. Commun. 307 2003 157 164 (Pubitemid 36808548)
24. S.Y. Kim, N. Suzuki, Y.R. Laxmi, B.P. McGarrigle, J.R. Olson, M. Sharma, M. Sharma, and S. Shibutani Formation of tamoxifen-DNA adducts in human endometrial explants exposed to alpha-hydroxytamoxifen Chem. Res. Toxicol. 18 2005 889 895 (Pubitemid 40705456)
25. P.L. Carmichael, A.H. Ugwumadu, P. Neven, A.J. Hewer, G.K. Poon, and D.H. Phillips Lack of genotoxicity of tamoxifen in human endometrium Cancer Res. 56 1996 1475 1479 (Pubitemid 26104004)
26. 32P-post-labelling for tamoxifen-DNA adducts in the human endometrium Carcinogenesis 20 1999 339 342 (Pubitemid 29057570)
27. S. Shibutani, A. Ravindernath, N. Suzuki, I. Terashima, S.M. Sugarman, A.P. Grollman, and M.L. Pearl Identification of tamoxifen-DNA adducts in the endometrium of women treated with tamoxifen Carcinogenesis 21 2000 1461 1467 (Pubitemid 30601641)
28. S. Shibutani, N. Suzuki, I. Terashima, S.M. Sugarman, A.P. Grollman, and M.L. Pearl Tamoxifen-DNA adducts detected in the endometrium of women treated with tamoxifen Chem. Res. Toxicol. 12 1999 646 653 (Pubitemid 29354748)
29. E.A. Martin, K. Brown, M. Gaskell, F. Al-Azzawi, R.C. Garner, D.J. Boocock, E. Mattock, D.W. Pring, K. Dingley, K.W. Turteltaub, L.L. Smith, and I.N. White Tamoxifen DNA damage detected in human endometrium using accelerator mass spectrometry Cancer Res. 63 2003 8461 8465 (Pubitemid 37549502)
30. 14C]-labeled therapeutic dose Cancer Res. 67 2007 6995 7002 (Pubitemid 47105548)
31. T. Hachisuga, T. Miyakawa, H. Tsujioka, S. Horiuchi, M. Emoto, and T. Kawarabayashi K-ras mutation in tamoxifen-related endometrial polyps Cancer 98 2003 1890 1897 (Pubitemid 37310231)
32. T. Hachisuga, H. Tsujioka, S. Horiuchi, T. Udou, M. Emoto, and T. Kawarabayashi K-ras mutation in the endometrium of tamoxifen-treated breast cancer patients, with a comparison of tamoxifen and toremifene Br. J. Cancer 92 2005 1098 1103 (Pubitemid 40546675)
33. V.C. Jordan, and C. Chem Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance Breast Cancer Res. Treat. 2 1982 123 138 (Pubitemid 13233530)
34. S.F. Teunissena, H. Rosinga, A.H. Schinkelb, J.H.M. Schellensc, and J.H. Beijnen Bioanalytical methods for determination of tamoxifen and its phase I metabolites: a review Anal. Chim. Acta 683 2010 21 37
35. J.M. Fromson, S. Pearson, and S. Bramah The metabolism of tamoxifen (I.C.I. 46,474). Part I. In laboratory animals Xenobiotica 3 1973 693 709
36. V.J. Wiebe, C.K. Osborne, W.L. McGuire, and M.W. DeGregorio Identification of estrogenic tamoxifen metabolite(s) in tamoxifen-resistant human breast tumors J. Clin. Oncol. 10 1992 990 994
37. R.R. Brown, R. Bain, and V.C. Jordan Determination of tamoxifen and metabolites in human serum by high-performance liquid chromatography with post-column fluorescence activation J. Chromatogr. 272 1983 351 358 (Pubitemid 13149624)
38. C. Murphy, T. Fotsis, P. Pantzar, H. Adlercreutz, and F. Martin Analysis of tamoxifen and its metabolites in human plasma by gas chromatography-mass spectrometry (GC-MS) using selected ion monitoring (SIM) J. Steroid Biochem. 26 1987 547 555 (Pubitemid 17066987)
39. G. Giorda, L. Franceschi, D. Crivellari, M.D. Magri, A. Veronesi, C. Scarabelli, and M. Furlanut Determination of tamoxifen and its metabolites in endometrial tissue of long-term treated women Eur. J. Cancer 36 Suppl. 4 2000 101 102
40. N.W. Gaikwad, L. Yang, P. Muti, J.L. Meza, S. Pruthi, J.N. Ingle, E.G. Rogan, and E.L. Cavalieri The molecular etiology of breast cancer: evidence from biomarkers of risk Int. J. Cancer 122 2008 1949 1957 (Pubitemid 351441183)
41. N.W. Gaikwad, L. Yang, S. Pruthi, J.N. Ingle, N. Sandhu, E. Rogan, and E. Cavalieri Urine biomarkers of risk in the molecular etiology of breast cancer Breast Cancer Basic Clin. Res. 3 2009 1 8
42. A.J. Swerdlow, and M.E. Jones Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study J. Natl. Cancer Inst. 97 2005 375 384 (Pubitemid 40425956)
43. K. Yamazawa, Y. Miyazawa, M. Suzuki, M. Wakabayashi, H. Kaku, and H. Matsui Tamoxifen and the risk of endometrial cancer in Japanese women with breast cancer Surg. Today 36 2006 41 46 (Pubitemid 43015853)
44. F. Sesti, L. Patrizi, B. Ermini, G. Palmieri, A. Orlandi, and E. Piccione High-grade endometrial stromal sarcoma after tamoxifen therapy for breast cancer Gynecol. Obstet. Invest. 60 2005 117 120 (Pubitemid 41159854)
45. A.M. Weli, and B. Lindeke Peroxidative N-oxidation and N-dealkylation reactions of pargyline Xenobiotica 16 1986 281 288 (Pubitemid 16164020)
46. G. Meunier, and B. Meunier Peroxidase-catalyzed O-demethylation reactions: quinone imine formation from 9-methoxyellipticine derivatives J. Biol. Chem. 260 1985 10576 10582 (Pubitemid 16252236)
47. A.M. Davies, E.A. Martin, R.M. Jones, C.K. Lim, L.L. Smith, and I.N.H. White Peroxidase activation of tamoxifen and toremifen resulting in DNA damage and covalently bound protein adducts Carcinogenesis 16 1995 539 545
48. N.W. Gaikwad, L. Yang, J. Vose, E. Rogan, and E. Cavalieri Urinary biomarkers suggesting etiology of non-Hodgkin's lymphoma Biomarkers 14 2009 502 512
49. N.W. Gaikwad, and W.J. Bodell Formation of DNA adducts by microsomal and peroxidase activation of p-cresol: role of quinone methide in DNA adduct formation Chem. Biol. Interact. 138 2001 217 229 (Pubitemid 33063637)
50. B. Moorthy, P. Sriram, D.N. Pathak, W.J. Bodell, and K. Randerath Tamoxifen metabolic activation: comparison of DNA adducts formed by microsomal and chemical activation of tamoxifen and 4-hydroxytamoxifen with DNA adducts formed in vivo Cancer Res. 56 1996 53 57 (Pubitemid 26010384)
51. D.N. Pathak, K. Pongracz, and W.J. Bodell Microsomal and peroxidase activation of 4-hydroxy-tamoxifen to form DNA adducts: comparison with DNA adducts formed in Sprague-Dawley rats treated with tamoxifen Carcinogenesis 16 1995 11 15
52. 32P-postlabeling analyses of tamoxifen-DNA adducts in humans J. Natl. Cancer Inst. 96 2004 1099 1104 (Pubitemid 39172412)
53. 32P-postlabeling Biochem. Biophys. Res. Commun. 320 2004 297 302 (Pubitemid 38798865)
54. M. Sharma Analysis of tamoxifen-DNA adducts by high-performance liquid chromatography using postcolumn online photochemical activation Biochem. Biophys. Res. Commun. 273 2000 40 44 (Pubitemid 30426859)
55. K. Pongracz, D.N. Pathak, T. Nakamura, A.L. Burlingame, and W.J. Bodell Activation of the tamoxifen derivative metabolite E to form DNA adducts: comparison with the adducts formed by microsomal activation of tamoxifen Cancer Res. 55 1995 3012 3015
56. J.L. Bolton, E. Comeau, and V. Vukomanovic The influence of 4-alkyl substituents on the formation and reactivity of 2-methoxy quinone methides: evidence that extended π-conjugation dramatically stabilizes the quinone methide formed from eugenol Chem. Biol. Interact. 95 1995 279 290
57. W.J. Bodell, Q. Ye, D.N. Pathak, and K. Pongracz Oxidation of eugenol to form DNA adducts and 8-hydroxy-2′-deoxyguanosine: role of quinone methide derivative in DNA adduct formation Carcinogenesis 19 1998 437 443 (Pubitemid 28375446)
58. D.N. Pathak, and W.J. Bodell DNA adduct formation by tamoxifen with rat and human liver microsomal activation system Carcinogenesis 15 1994 529 532 (Pubitemid 24121703)
59. 32P-postlabeling test for structurally diverse DNA adducts Carcinogenesis 7 1986 1543 1551
60. M. Sharma, D.E. Shubert, M. Sharma, J. Lewis, B.P. McGarrigle, and D.P. Bofinger Biotransformation of tamoxifen in a human endometrial explant culture model Chem. Biol. Interact. 146 2003 237 249 (Pubitemid 37464853)
61. L.M. Notley, K.H. Crewe, P.J. Taylor, M.S. Lennard, and E.M.J. Gillam Characterization of the human cytochrome P450 forms involved in metabolism of tamoxifen to its α-hydroxy and α,4-dihydroxy derivatives Chem. Res. Toxicol. 18 2005 1611 1618 (Pubitemid 41504482)
62. H.K. Crewe, L.M. Notley, R.M. Wunsch, M.S. Lennard, and E.M.J. Gillam Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4′-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen Drug Metab. Dispos. 30 2002 869 874 (Pubitemid 34815415)
63. N.W. Gaikwad, and W.J. Bodell Formation of DNA adducts in HL-60 cells treated with the toluene metabolite p-cresol: a potential biomarker for toluene exposure Chem. Biol. Interact. 145 2002 149 158 (Pubitemid 36398428)
64. L. Yang, N.W. Gaikwad, J. Meza, E. Cavalieri, P. Mutti, B. Trock, and E. Rogan Novel biomarkers for the risk of prostate cancer: results from case-control study Prostate 69 2009 41 48
65. T. Sakamoto, H. Eguchi, Y. Omoto, T. Ayabe, H. Mori, and S.-I. Hayashi Estrogen receptor-mediated effects of tamoxifen on human endometrial cancer cells Mol. Cell. Endocrinol. 192 2002 93 104 (Pubitemid 34669917)
66. M.-C. King, S. Wieand, K. Hale, M. Lee, T. Walsh, and K. Owens Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) breast cancer prevention trial J. Am. Med. Assoc. 286 2001 2251 2256 (Pubitemid 33063147)